Development of therapeutic monoclonal antibodies for emerging arbovirus infections

Butantan affiliation
External affiliation
Publication type
Access rights
Open access
Terms of use
Appears in Collections:
Antibody-based passive immunotherapy has been used effectively in the treatment and prophylaxis of infectious diseases. Outbreaks of emerging viral infections from arthropod-borne viruses (arboviruses) represent a global public health problem due to their rapid spread, urging measures and the treatment of infected individuals to combat them. Preparedness in advances in developing antivirals and relevant epidemiological studies protect us from damage and losses. Immunotherapy based on monoclonal antibodies (mAbs) has been shown to be very specific in combating infectious diseases and various other illnesses. Recent advances in mAb discovery techniques have allowed the development and approval of a wide number of therapeutic mAbs. This review focuses on the technological approaches available to select neutralizing mAbs for emerging arbovirus infections and the next-generation strategies to obtain highly effective and potent mAbs. The characteristics of mAbs developed as prophylactic and therapeutic antiviral agents for dengue, Zika, chikungunya, West Nile and tick-borne encephalitis virus are presented, as well as the protective effect demonstrated in animal model studies.
Ormundo LT., Barreto C, Tsuruta LR. Development of therapeutic monoclonal antibodies for emerging arbovirus infections. Viruses. 2023, Oct; 15, 11: 2177. doi:10.3390/v15112177.
Link to cite this reference
Journal title
Issue Date

Files in This Item:

Size: 1.3 MB
Format: Adobe PDF
Show full item record

This item is licensed under a Creative Commons License Creative Commons